Heather Duncan

Heather J Duncan

Field Service Professor

Education

Bachelor's Degree, University of California 1975 (Biology and Psychology)

Master's Degree, Columbia University 1976 (Psychology)

PhD, The American University 1984 (Psychology)

Positions and Work Experience

2009 -To Present Field Service Associate Professor, Department of Internal Medicine, Division of Nephrology , University of Cincinnati College of Medicine,

2004 -2009 Field Service Assistant Professor, Department of Internal Medicine, Division of Nephrology , University of Cincinnati College of Medicine,

2004 -To Present Research Associate, The University Hospital, Cincinnati, OH

1996 -2004 Senior Research Associate, Department of Internal Medicine, Division of Nephrology and Hypertension, University of Cincinnati College of Medicine,

1996 -To Present Research Coordinator, Dialysis Clinic, Inc., Cincinnati, OH

1991 -2005 Director, University of Cincinnati Taste and Smell Center, Cincinnati, OH

1989 -1995 Research Assistant Professor, Department of Otolaryngology - Head and Neck Surgery, University of Cincinnati College of Medicine,

1988 -1991 Assistant Director, University of Cincinnati Taste and Smell Center, Cincinnati, OH

1987 -1989 Postdoctoral Assistant, Department of Anatomy and Cell Biology, Neurobiology Division, University of Cincinnati College of Medicine,

1980 -1983 Program Assistant, Sensory Physiology and Perception and Developmental Neurosciences, Division of Behavioral Neural Sciences, National Science Foundation, Washington, D.C.

Research and Practice Interests

Clinical Trials for CKD and Dialysis, Outcomes Research in ESRD Population

Research Support

Investigators:Duncan H 2011 -To Present Burden of AV Graft and Fistual Complications in Chronic Kidney Disease Patients (GRAFIC) Role:Sub-Investigator Active

Investigators:Duncan H 2011 -To Present A three-Period, 58-Week Safety and Efficacy Trial of XXX patients with End-Stage Renal Disease (ESRD) on Dialysis Role:Sub-Investigator Active

Investigators:Duncan H 2011 (REPAIR-IDA): Randomized Evaluation of Efficacy and Safety of XXX in Patients with Iron Deficiency Anemia and Impaired Renal Function Role:Sub-Investigator Completed

Investigators:Duncan H 2011 -To Present An Observational Prospective Registry to Identify Demographic and Clinical Characteristics of Patients Hospitalized with Euvolemic and Hypervolemic Hyponatremia and Assess the Comparative Effectiveness of Available Treatments and the Impact on Resource Utilization Role:Sub-Investigator Active

Investigators:Duncan H 2011 -To Present A Multi-Center, Longitudinal, Observational Study of Patients with Autosomal Dominant Polycystic Kidney Disease (ADPKD) to Establish the Rate, Characteristics, and Determinants of Disease Progression Role:Sub-Investigator Active

Investigators:Duncan H 2011 -2012 XXX Evaluation in Patients with Chronic Kidney Disease and Type 2 Diabetes: The Occurrence of Renal Events Role:Sub-Investigator Active

Investigators:Duncan H 2011 -To Present A Randomized, Double-Blind, Placebo-Controlled, Phase III Study of Dialysate Containing XXX in Chronic Kidney Disease Patients Receiving Hemodialysis: The Continuous Replacement Using Iron Soluble Equivalents Study Role:Sub-Investigator Active

2011 A Randomized, Double-Blind, Placebo-Controlled, Repeat Dose, Safety, Efficacy and Pharmacokinetic/Pharmacodynamic Study of XXX in Subjects with Chronic Kidney Disease, Vitamin D Insufficiency and Secondary Hyperparathyroidism Role:Sub-Investigator Completed

Investigators:Duncan H 2010 -2011 A 4-Week Dose-Ranging and Efficacy Trial of XXX in Patients with End-Stage Renal Disease (ESRD) Following a Two-Week Washout Period Role:Sub-Investigator Completed

Investigators:Duncan H 2009 -2012 Vitamin D and Secondary Hyperparathyroidism in CKD Patients Role:PI Completed

Investigators:Duncan H 2008 -2010 A Multi-Center, Randomized, Double-Blind Study to Evaluate the Efficary and Safety of XXX Versus YYY in Patients with Type 2 Diabetes Mellitus and End-Stage Renal Disease Who are on Dialysis and Who Have Inadequate Glycemic Control Role:Sub-Investigator Completed

Investigators:Duncan H 2009 A Phase 2, Randomized, Open-Label, Single-Dose Study of Oral and Intravenous XXX Evaluating Pharmacokinetics, Pharmacodynamics, and Safety in Subjects with Stage 3 and 4 Chronic Kidney Disease, with Vitamin D Insufficiency and Secondary Hyperparathyroidism Role:Sub-Investigator Completed

Investigators:Duncan H 2009 A Randomized, Double-Blind, Placebo-Controlled, Dose-Ranging Study Using XXX and YYY in Hyperphosphatemic Chronic Kidney Disease Patients on Hemodialysis Role:Sub-Investigator Completed

Investigators:Duncan H 2008 -To Present A Phase 1-2, Multi-Center, Dose Escalation Study of a Single Dose of XXX Administered Immediately after Ateriovenous Fistula Creation in Patients with Chronic Kidney Disease Role:Sub-Investigator Active

Investigators:Duncan H 2008 -2009 A Randomized, Single-Blind, Placebo-Controlled, 4-Week Treatment Study of the Safety and Biologic Activity of Escalating Multiple Oral Doses of XXX in Subjects with Chronic Kidney Disease not Requiring Dialysis Role:Sub-Investigator Completed

Investigators:Duncan H 2008 -2009 A Single-Dose, Open-Label, Dose Determination, Randomized, Cross-Over, Pharmacokinetic Study of XXX Injection and YYY Injection in Subjects with Stage 5 Chronic Kidney Disease and Secondary Hyperparathyroidism on Hemodialysis Role:Sub-Investigator Completed

Investigators:Duncan H 2008 -2011 A 30-Week, Multi-center, Randomized, Double-Blind, Parallel-Group Study of the Combination of XXX and YYY Compared to YYY Monotherapy in Dyslipidemic Subjects with Stage 3 Chronic Kidney Disease Role:Sub-Investigator Completed

Investigators:Duncan H 2008 -2009 A Multi-Center, Randomized, Controlled Study to Investigate the Safety and Tolerability of Intravenous XXX vs. Standard Medical Care in Treating Iron Deficiency Anemia in Chronic Kidney Disease Patients Role:Sub-Investigator Completed

Investigators:Duncan H 2008 -2010 A Dose-Ranging Study of Dialysate Containing XXX Versus Control in Subjects with ESRD Receiving Chronic Hemodialysis Role:Sub-Investigator Completed

Investigators:Duncan H 2008 A Phase III, Randomized, Double-Blind, Placebo-Controlled Study of XXX for Restoration of Function in Dysfunctional Hemodialysis Catheters Role:Sub-Investigator Completed

Investigators:Duncan H 2008 -2009 A Phase 2/3, Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Safety and Efficacy of XXX in Subjects with Class III or IV Lupus Nephritis in Combination with Mycophenolate Mofetil Therapy Role:Sub-Investigator Completed

Investigators:Duncan H 2008 -2010 Safety and Efficacy of XX Treatment after the Creation of Arteriovenous Access for Hemodialysis Use - An Extension Study Role:Sub-Investigator Completed

Investigators:Duncan H 2008 -2010 A Multi-Center, Randomized, Double-Blind, Active-Controlled Clinical Trial to Evaluate the Safety and Tolerability of 24 weeks treatment with XXX (50mg qd) versus YYY (25 mg qd) in Patients with Type 2 Diabetes and Severe Renal Insufficiency Role:Sub-Investigator Completed

Investigators:Duncan H 2008 -2010 Chart Review: Gender Differences in Hemodialysis Access Success Role:PI Completed

Investigators:Duncan H 2008 -2010 A Phase 3, Randomized, Active-Controlled, Open-Label, Multi-Center Study of the Safety and Efficacy of XXX Injection for the Maintenance Treatment of Anemia in Hemodialysis Patients Previously Treated with Epoetin ALfa Role:Sub-Investigator, Coordinator Completed

Investigators:Duncan H 2007 -To Present A Phase III, Randomized, Double-Blind, Placebo-Controlled Study of XXX for Prevention of Chronic Kidney Disease Progression in Patients with Moderate to Severe Chronic Kidney Disease Including Assessment of Quality of Life Role:Sub-Investigator, Coordinator Active

Investigators:Duncan H 2007 -To Present Shire SELECT A Phase IV, Long-Term, Observational Safety Study in End Stage Renal Disease Subjects Treated with XXX Role:Sub-Investigator Active

Investigators:Duncan H 2007 -2011 A Long-Term Safety Study of the XXX after Surgical Implantation with the Lifespan ePTFE Vascular Graft in the Upper Extremity for Hemodialysis Vascular Access Role:Sub-Investigator Completed

Investigators:Duncan H 2006 -2009 HAPPI: Hemodialysis Access Patency Extension with Percutaneous Transluminal Infusion of XXX Role:Sub-Investigator, Coordinator Completed

Investigators:Duncan H 2006 -To Present EVOLVE: Evaluation of XXX Therapy to Lower Cardiovascular Events Role:Sub-Investigator, Coordinator Active

Investigators:Duncan H 2006 -2009 ADVANCE: A Randomized Study to Evaluate the Effects of XXX Plus Low Dose Vitamin D on Vascular Calcification in Subjects with Chronic Kidney Disease (CKD) Receiving Hemodialysis Role:Sub-Investigator, Coordinator Completed

Investigators:Duncan H 2006 -2007 A Phase 4, Multi-Center, Open-Label, Randomized Study to Determine Clinically Appropriate Doses of XXX when Converting from YYY for the Treatment of Secondary Hyperparathyroidism in Stage 5 Chronic Kidney Disease (CKD) Subjects on Hemodialysis Role:Sub-Investigator, Coordinator Completed

Investigators:Duncan H 2006 -2009 A Randomized, Single Blind Trial to Assess the Effectiveness of Maintaining Patency and Safety of the XXX after Surgical Implantation with the Lifespan ePTFE Vascular Graft in the Upper Extremity for Hemodialysis Vascular Access Role:Sub-Investigator, Coordinator Completed

Investigators:Duncan H 2006 -To Present Chart Review: Hemodialysis Catheters and Infection Control Role:PI Active

Investigators:Duncan H 2006 -2008 Safety of XXX in the Creation of Arteriovenous Access for Hemodialysis Use Role:Sub-Investigator, Coordinator Completed

Investigators:Duncan H 2006 -2007 A Phase 2 Randomized Study of the Safety and Efficacy of XXX in Subjects with Renal Anemia Not Requiring Dialysis and Not Receiving Recombinant Human Erythropoietin Role:Sub-Investigator, Coordinator Completed

Investigators:Duncan H 2005 -2008 A Pilot Phase II Trial of XXX for the Prevention of Vascular Access Graft Failure in Patients Undergoing Hemodialysis Role:Sub-Investigator, Coordinator Completed

Investigators:Duncan H 2005 -2010 An Open-Label, Multi-Center Study to Document the Efficacy, Safety and Tolerability of Long-Term Administration of XXX in Patients with Chronic Renal Anemia Role:Sub-Investigator, Coordinator Completed

Investigators:Duncan H 2004 -To Present Potassium Channels in Lymphocytes: Comparison between Patients with Lupus Erythematosus and Other Autoimmune Diseases and Normal Controls Role:Sub-Investigator, Coordinator Active

Investigators:Duncan H 2004 -2006 Trial to Reduce Carviovascular Events with XXX Therapy (TREAT) Role:Sub-Investigator, Coordinator Completed

Investigators:Duncan H 2004 A Phase III Study of the Safety and Efficacy of Two Parenteral Dose Regimens of XXX (compared with oral iron) as an Iron Replacement - Therapy in Hemodialysis Patients who are Receiving Supplemental EPO therapy Role:Sub-Investigator, Coordinator Completed

Investigators:Duncan H 2004 -2005 A Phase 3, Randomized, Placebo-Controlled, Double-Blind, Multi-Center Study to Evaluate the Safety and Efficacy of XXX in Reducing Serum Intact Parathyroid Hormone Levels in Chronic Kidney Disease Stage 5 Subjects on Hemodialysis or Peritoneal Dialysis Role:Sub-Investigator Completed

Investigators:Duncan H 2004 -2005 A Phase III Study of the Safety and Efficacy of XXX (compared with oral iron) as an Iron Replacement Therapy in Chronic Kidney Disease for Patients not on Dialysis Role:Sub-Investigator, Coordinator Completed

Investigators:Duncan H 2004 -2005 A Phase 3, Multicenter, Randomized, Placebo-Controlled, Double-Blind Study to Evaluate Efficacy of XXX in Adults on Hemodialysis Role:Sub-Investigator, Coordinator Completed

Investigators:Duncan H 2004 -2005 A Randomized, Controlled, Open-Label, Multi-Center, Parallel-Group Study to Demonstrate the Efficacy and Safety of XXX when Administered Intravenously for the Maintenance Treatment of Anemia in Patients with Chronic Kidney Disease who are on Dialysis Role:Sub-Investigator, Coordinator Completed

Investigators:Duncan H 2004 A Study of the Efficacy and Safety of XXX in Anemic Patients Receiving Peritoneal Dialysis Role:Sub-Investigator, Coordinator

Investigators:Duncan H 2004 -2006 A Phase IV, Prospective, Randomized, Active-Controlled, Double-Blind, Double-Dummy, Multi-Center Study to Evaluate the Survival Benefits of XXX to YYY in Subjects with Stage V Chronic Kidney Disease on Hemodialysis Role:Sub-Investigator, Coordinator Completed

Investigators:Duncan H 2003 -2005 Multi-Center, Randomized, Double-Blind, Placebo-Controlled, Efficacy and Safety Study of the Effects of XXX in Patients with Hyponatremia Role:Sub-Investigator, Coordinator Completed

Investigators:Duncan H 2003 -2005 A Multi-Center, Randomized, Open-Label Study to Compare the Efficacy and Safety of an XXX When Two Different Vitamin D Regimens are Used in Subjects with Secondary Hyperparathyroidism of End-Stage Renal Disease (ESRD) Role:Sub-Investigator, Coordinator Completed

Investigators:Duncan H 2002 -2004 A Randomized, Double-Blind Study Comparing XXX and YYY in the Treatment of Anemia in African American Subjects with Chronic Renal Failure (CRF) Receiving Hemodialysis Role:Sub-Investigator, Coordinator Completed

Investigators:Duncan H 2002 -2003 A Placebo-Controlled, Double-Blind, Extension Study to Assess the Long-Term Safety of an XXX in Secondary Hyperparathyroidism of End-Stage Renal Disease Role:Sub-Investigator, Coordinator Completed

Investigators:Duncan H 2002 -2006 Correction of Hemoglobin and Outcomes in Renal Insufficiency (CHOIR) Role:Sub-Investigator, Coordinator Completed

Investigators:Duncan H 2002 -2004 XXX for Maintenance Phase Treatment (PROMPT) Role:Sub-Investigator, Coordinator Completed

Investigators:Duncan H 2002 -2004 A Phase III, Prospective, Randomized, Placebo-Controlled, Double-Blind, Multi-Center Study to Determing the Safety and Efficacy of XXX (Dosed Three Times Weekly) in Reducing Elevated Serum Intact Parathyroid Hormone Levels in Subjects with Chronic Kidney Disease Role:Sub-Investigator, Coordinator Completed

Investigators:Duncan H 2002 -2003 A Phase III, Prospective, Placebo-Controlled, Double-Blind, Randomized,Multi-Center Study to Evaluate the Safety and Efficacy of XXX in Reducing Serum Intact Parathyroid Hormone Levels in End Stage Renal Disease Subjects on Peritoneal Dialysis Role:Sub-Investigator, Coordinator Completed

Investigators:Duncan H 2002 A Phase 3 Study to Assess the Efficacy and Safety of an XXX in Secondary Hyperparathyroidism of End Stage Renal Disease Treated with Hemodialysis Role:Sub-Investigator, Coordinator Completed

Investigators:Duncan H 2000 -2001 A Study Evaluating the Initiation and Titration of Fixed Doses of XXX Therapy in Subjects with Chronic Renal Insufficiency (CRI) Role:Sub-Investigator, Coordinator Completed

Investigators:Duncan H 2000 -2001 Prevalence of Anemia in Patients with Early Renal Insufficiency Role:PI, Study Coordinator Completed

2001 Clinical Evaluation of XXX Dosed Once Weekly in Patients with Anemia Due to Early Renal Insufficiency (POWER) Role:Sub-Investigator, Coordinator Completed

Investigators:Duncan H 1999 -2001 A Phase III Randomized Study Comparing XXX versus Observation Only, following Angioplasty for Prevention of Restenosis in Hemodialysis Patients Role:Sub-Investigator, Coordinator Completed

Investigators:Duncan H 1999 -2000 A Prospective Trial of the XXX to Evaluate its Safety and Effectiveness in Chronic Hemodialysis Role:Sub-Investigator, Coordinator Completed

Investigators:Duncan H 1996 -2007 CHOICE (Choices for Healthy Outcomes in Caring for ESRD) Cohort Study Role:Co-Investigator, Study Coordinator Completed

Investigators:Duncan H 1994 -1998 Chemosensory Dysfunction and Malnutrition in Dialysis Role:PI, Study Coordinator Completed

Investigators:Duncan H 1997 Evaluation of a Dietary Supplement for Dialysis and Transplant Patients - Phase 1 Clinical Trial to Determine Safety and Efficacy Role:Co-Investigator Completed

Grant: #U01 DK082218 Investigators:Banerjee, Rupak; Duncan, Heather; El-Khatib, Mahmoud; Lee, Timmy; Munda, Rino; Roy-Chaudhury, Prabir; Succop, Paul; Tevar, Amit; Woodle, Ervin Steve; Wu, Tianying 09-10-2008 -05-31-2014 National Inst of Diabetes and Digestive and Kidney Disease Clinical, Hemodynamic and Biological Markers of AV Fistula Maturation Role:Collaborator $1,382,449.00 Active Level:Federal

Publications

Published Abstracts

Vyakaranam S, Duncan H, Meganathan K, Kant K (2011. )Gentamicin catheter locks: and markers for development of resistance and clinical outcomes in one urban outpatient dialysis center .[Abstract]Journal of American Society of Nephrology,

El-Khatib M, Duncan H, Kant K (2011. )The effect of bundled payment system on the utilization of erythropoiesis stimulating agent therapy .[Abstract]Journal of American Society of Nephrology,

El-Khatib M, Kant K, Duncan H (2010. )Factors influencing longevity of dialysis catheters .[Abstract]Journal of American Society of Nephrology,

Kant K, Duncan H, El-Khatib M (2010. )Permanent dialysis with a catheter: fact and fiction OR one size does not fit all .[Abstract]Journal of American Society of Nephrology,

El-Khatib M, Kant K, Duncan H (2010. )Pentoxifylline improves erythropoietin resistance: possible mechanisms .[Abstract]Journal of American Society of Nephrology,

Kant K, Duncan H, Hennessy J (2009. )Vitamin D stores in CKD5: does 25-OH D status influence management of HPTH in dialysis patients .[Abstract]Journal of American Society of Nephrology,

Lee T, Ullah A, Duncan A, El-Khatib M, Roy-Chaudhury P (2009. )Aggressive interventions for fistula maturation: a double-edged sword? .[Abstract]Journal of American Society of Nephrology,

Kant K, El-Khatib M, Duncan H (2009. )Use of antibiotic locking solutions to decrease hemodialysis catheter-related bacteremia: long-term impact on CRB rates and bacterial resistance .[Abstract]Journal of American Society of Nephrology, 2009 ,

El-Khatib M, Duncan H (2008. )Dialysis catheter locks, bacteremia, and erythropoietin (EPO) requirements .[Abstract]Journal of American Society of Nephrology, 19 ,465A

Kant K, Duncan H, Tallarico B, McKinney R, Diadato C (2008. )Does the buttonhole technique of AV fistula cannulation increase risk of bacteremia? .[Abstract]Journal of American Society of Nephrology, 19 ,262A

Lee T, Duncan H (2008. )Gender disparities exist in arteriovenous fistula maturation .[Abstract]Journal of American Society of Nephrology, 19 ,260A

El-Khatib M, Duncan H (2008. )Variation in erythropoietin (ESA) requirements among patients on hemodialysis .[Abstract]Journal of American Society of Nephrology, 19 ,899A

El-Khatib M, Duncan H (2007. )Factors affecting erythropoietin (ESA) requirements in stable dialysis patients .[Abstract]Journal of American Society of Nephrology, 18 ,908A

Kant K, Ghandra S, Menke S, El-Khatib M, Duncan H (2007. )Measurements of hemodialysis adequacy - URR, Kt/VF, blood volume processed: which measure best predicts hospitalization? .[Abstract]Journal of American Society of Nephrology, 18 ,898A

Duncan H, Dhingra P, Beiting M, McKinney R, El-Khatib M, Kant K (2007. )Efficacy of lower gentamicin catheter lock on catheter-related bacteremias and metastatic infections .[Abstract]Journal of American Society of Nephrology, 18 ,462A

El-Khatib M, Duncan H (2007. )Association between type of hemodialysis and erythropoietin (ESA) requirement .[Abstract]Journal of American Society of Nephrology, 18 ,465A

El-Khatib M, Duncan M, Kant K (2006. )Association between dialysis access and c-reactive protein (CRP) .[Abstract]Journal of American Society of Nephrology, 17 ,498A

El-Khatib M, Duncan H, Kant K (2006. )The usefulness of hemoglobin content of reticulocytes (CHr) in anemia management in dialysis patients .[Abstract]Journal of American Society of Nephrology, 17 ,581A

Duncan H, Kant K, El-Khatib M (2006. )Hemodialysis central venous catheters and infection control .[Abstract]Journal of American Society of Nephrology, 17 ,581A

Duncan H, Kant K, El-Khatib M (2006. )Hemodialysis central venous catheters and infection control .[Abstract]Journal of American Society of Nephrology, 17 ,589A

Nica R, Duncan H, Kant K, El-Khatib M (2006. )Is blood volume processed a new parameter to evaluate hemodialysis adequacy? .[Abstract]Journal of American Society of Nephrology, 240 ,867A

Nicolaou S, Szigligeti P, Duncan H, Neumeier L, Lee S, Kant S, Filipovich A, Conforti L (2006. )Altered dynamics of Kc1.3 channel compartmentalization in the immunological synapse in systemic lupus erythematosus .[Abstract]J Clinical Immunology, 119 ,568

Nica R, Duncan H, Halukurike V, Kant K (2005. )Is calciphylaxis a poor dialysis? .[Abstract]Journal of American Society of Nephrology, 16 ,282A

El-Khatib M, Duncan H, Kant K (2005. )C-reactive protein, reticulocyte hemoglobin content and inflammatory markers in iron management and erythropoietin resistance in dialysis patients .[Abstract]Journal of American Society of Nephrology, 16 ,478A

El-Khatib M, Kant K, Duncan H (2003. )Iron management guided bu CHr in dialysis patients with high ferritin level .[Abstract]Journal of American Society of Nephrology, 14 ,706A

El-Khatib M, Kant K, Duncan H (2003. )CHr, CRP and erythropoietin resistance in dialysis patients .[Abstract]Journal of American Society of Nephrology, 14 ,708A

Halukurike V, Nica R, Duncan H, Freyberg M, Hornung R, Kant K (2003. )Risk factors for calciphylaxis: a case control study .[Abstract]Journal of American Society of Nephrology, 14 ,856A

Roy-Chaudhury P, Kelly B, Turner R, Munda R, Duncan H, Zhang J, Heffelfinger S (2003. )Defining the phenotype of venous neointimal cells with smoothelin .[Abstract]Journal of American Society of Nephrology, 14 ,508A

Kant K, Duncan H, Dhingra P, Roy-Chaudhury P (2003. )Vascular access thrombosis: role of lipoprotein (a) and acute phase reactants .[Abstract]Journal of American Society of Nephrology, 14 ,507A

El-Khatib M, Kant K, Duncan H (2002. )The use of reticulocyte hemoglobin content to determine IV iron administration in hemodialysis unit .[Abstract]Journal of American Society of Nephrology, 13 ,716A

El-Khatib M, Kant K, Duncan H (2002. )Reticulocyte hemoglobin content as a diagnostic test for IV iron administration in peritoneal dialysis patients .[Abstract]Journal of American Society of Nephrology, 13 ,394A

Roy-Chaudhury P, Faiyaz R, Kant K, Kelly B, Duncan H (2002. )HMG coenzyme reductase inhibitors for hemodialysis vascular access dysfunction .[Abstract]Journal of American Society of Nephrology, 13 ,

Duncan H, Narayana A, Zuckerman D, Alspaugh J, Vu D, Kant K, Faiyaz R, Kelly B, Roy-Chaudhury P (2001. )External radiationtherapy for hemodialysis vascular access dysfunction .[Abstract]Journal of American Society of Nephrology, 12 ,287A

Roy-Chaudhury P, Waters L, Miller M, Reaves A, Armstrong J, Duncan H, Munda R, Kelly B, Heffelfinger S (2001. )Adventitial fibroblasts contribute to venous neointimal hyperplasia (VNH) in PTFE dialysis grafts .[Abstract]Journal of American Society of Nephrology, 12 ,287A

Faiyaz R, Duncan H, Zuckerman D, Alspaugh J, Munda R, Kelly B, Kant K, Roy-Chaudhury P (2001. )Increase in vascular access bloodflow following venous angioplasty determines PTFE graft survival .[Abstract]Journal of American Society of Nephrology, 12 ,288A

Duncan H, Faiyaz R, Kelly B, Kant K, Roy-Chaudhury P (2001. )Prognostic determinants for hemodialysis vascular graft survival .[Abstract]Journal of American Society of Nephrology, 12 ,287A

Pittman S, Govil A, Sorn L, Bissler G, Schultz T, Faith J, Kant K, Roy-Chaudhury P, Duncan H (2001. )Alternative medicine use in dialysis patients: potential for good and bad! .[Abstract]Journal of American Society of Nephrology, 12 ,343A

Duncan H, Pittman S, Peterson D (1999. )Serum phosphate is independently associated with PTH in ESRD patients receiving Calcitriol .[Abstract]Journal of American Society of Nephrology, 10 ,599A

Duncan H, Pittman S, Heile S, Sorn L, Manzoor K, Kant K, Roy-Chaudhury P (1999. )Alternative medicine use by hemodialysis patients .[Abstract]Journal of American Society of Nephrology, 12 ,162A

Hastings L, Duncan H, Miller M (1997. )The therapeutic effects of fluticasone propionate on recover of function in the olfactory system .[Abstract]Chemical Senses, 22 ,698

Seiden A, Duncan H (1997. )The diagnosis of conductive olfactory loss .[Abstract]Chemical Senses, 22 ,789

Duncan H, Galla J (1997. )Changes in chemosensory dysfunction and nutritional state in the first two years of dialysis .[Abstract]Chemical Senses, 22 ,675

Duncan H, Frank R, Kues J, Johnson L, Warshaw G, Heacock P, Heile S, Norton P, galla J (1995. )Chemosensory complaints and their relationships to malnutrition in ESRD patients .[Abstract]Chemical Senses, 20 ,689

Newman P, hastings L, Duncan H, Frank R (1994. )The conditioning of anxiety to an odor: a possible mechanism of symptom maintenance in 'Sick Building Syndrome' .[Abstract]Chemical Senses, 19 ,529

Duncan H, Kues J, Heacock P, Heile S, Norton P, Johnson L, Galla J (1994. )Malnutrition in hemodialysis (HD) patients correlates with chemosensory disorders (CSD) .[Abstract]Clinical Research, 42 ,171A

Rothschiled M, Duncan H, Myer C III (1994. )Olfactory disturbance in pediatric tracheotomy .[Abstract]American Academy of Otolaryngology, Fall ,

Peer Reviewed Publications

Nicolaou S, Neumeier L, Takimoto K, Lee S, Duncan H, Kant K, Mongey A, Filipovich A, Conforti L (2010. )Differential calcium signaling and Kv1.3 trafficking to the immunological synapse in systemic lupus erythematosus.Cell calcium, ,47 (1 ),19-28

Nicolaou S, Szigligeti P, Neumeier L, Lee S, Duncan H, Kant K, Mongey A, Filipovich A, Conforti L (2007. )Altered dynamics of Kv1.3 channel compartmentalization in the immunological synapse in systemic lupus erythematosus .Journal of Immunology (Baltimore, Md. : 1950), ,179 (1 ),346-56

Duncan H, Pittman S, Govil A, Sorn L, Bissler G, Schultz T, Faith J, Kant, S, Roy-Chaudhury P (2007. )Alternative medicine use in dialysis patients: potential for good and bad!.Nephron. Clinical practice, ,105 (3 ),c108-13

El-Khatib M, Duncan H, Kant K (2006. )Role of C-reactive protein, reticulocyte haemoglobin content and inflammatory markers in iron and erythropoietin administration in dialysis patients.Nephrology (Carlton, Vic.), ,11 (5 ),400-4

Roy-Chaudhury P, Kelly B, Zhang J, Narayana A, Desai P, Melham M, Duncan H, Heffelfinger S (2003. )Hemodialysis vascular access dysfunction: from pathophysiology to novel therapies .Blood Purification, ,21 (1 ),99-110

Roy-Chaudhury, Prabir; Duncan, Heather; Barrett, William; Elson, Howard; Narayana, Ashwath; Foley, Jeri; Misra, Sanjay; Lynch, Pia Mikkelsen; Zuckerman, Darryl (2003. )Vascular brachytherapy for hemodialysis vascular access dysfunction: exploring an unmet clinical need .The Journal of Invasive Cardiology, ,15 Suppl A ,25A-30A

Roy-Chaudhury, Prabir; Kelly, Burnett S; Narayana, Ashwath; Desai, Pankaj; Melhem, Murad; Munda, Rino; Duncan, Heather; Heffelfinger, Sue C (2002. )Hemodialysis vascular access dysfunction from basic biology to clinical intervention .Advances in Renal Replacement Therapy, ,9 (2 ),74-84

Kant, K Shashi; Cook, E Francis; Duncan, Heather; Freyberg, Ron (2002. )Parathyroid hormone suppression by intravenous calcitriol: role of phosphate, calcium, race and diabetes .The American Journal of the Medical Sciences, ,323 (4 ),210-5

Duncan HJ (2001. )Introduction to Taste and Smell Dysfunction .Renal Nutrition Forum, ,20 (1 ),3-7

Seiden A, Duncan H (2001. )The Diagnosis of a Conductive Olfactory Loss .Laryngoscope, ,111 (9-14 ),

Duncan H (2001. )Taste and Smell Dysfunction: Clinical and Legal Issues .ChemoSense, ,3 (1-2, 8-10 ),

Tami T, Duncan H, Pfleger M (1998. )The identification of obstructive sleep apnea in patients who snore .Laryngoscope, ,108 ,508-513

Duncan H (1995. )How well can you smell? .Health Confidential , ,9, 12

Duncan H, Seiden A (1995. )Long-term follow-up of olfactory loss secondary to head trauma and upper respiratory infection .Archives of Otolaryngology - Head and Neck Surgery, ,121 ,1183-1187

Rothschild M, Myer C III, Duncan H (1995. )Olfactory disturbance in pediatric tracheotomy .Otolaryngology - Head and Neck Surgery, ,113 ,71-76

Duncan H, Beauchamp G, Yamazaki K (1992. )Assessing odor generalization in the rat; a sensitive technique .Physiology and Behavior, ,52 ,717-720

Paik S-I, Lehman M, Seiden A, Duncan H, Smith D (1992. )Human olfactory biopsy: the influence of age and receptor distribution .Archives of Otolaryngology - Head and Neck Surgery, ,118 ,731-738

Heth G, Nevo E, Ikan R, Weinstein V, Ravid U, Duncan H (1992. )Differential olfactory perception of enantiomeric compounds by blind subterranean mole rats (Spalax ehrenbergi) .Experientia, ,48 ,897-902

Duncan H, Slotnick B (1990. )Comparison of visual and olfactory reversal learning in pigeons .Chemical Senses, ,15 ,59-73

Duncan H, Nickell W, Shipley M, Gesteland R (1990. )Organization of projections from olfactory epithelium to olfactory bulb in the frog Rana Pipiens .Journal of Comparative Neurology, ,299 ,299-311

Book Chapter

Roy-Chaudhury P, Kelly B, Narayana A, Desai P, Melhem M, Duncan H, Heffelfinger S (2002 )Hemodialysis Vascular Access Function: from Bedside to Bench to Bedside Vascular Access for Hemodialysis VIII .Precept Press

Duncan H (1997 )Post-Viral Olfactory Loss Taste and Smell Disorders .(pp. 72-78).Thieme Medical Publishers

Duncan H, Smith D (1995 )Clinical Disorders of Olfaction: A Review Handbook of Olfaction and Gustation .(pp. 345-365).New York,Marcel Dekker

Duncan H, Smith D (1994 )Modifiability of NaCl Taste Aversion Generalization Functions Olfaction and Taste XI .(pp. 494).Tokyo, Japan,Springer-Verlag

Smith D, Duncan H (1992 )Primary Olfactory Disorders: Anosmia Hyposmia and Dysosmia Science of Olfaction .(pp. 439-466).New York,Springer Verlag

Seiden A, Duncan H, Smith D (1992 )Office Management of Taste and Smell Disorders Office Management of Taste and Smell Disorders .(pp. 817-835).Philadelphia, PA,

Beauchamp G, Yamazaki K, Duncan H, Bard J, Boyse E (1991 )Genetic Determination of Mouse Odor Chemical Signals in Vertebrates V .(pp. 244-254).Oxford,Oxford University Press

Presentations

Poster Presentations

Duncan H, Galla J (11-1996. )Changes in chemosensory dysfunction in dialysis patients and their relationship to malnutrition .American Society of Nephrology,

Duncan H, Willging J (09-1995. )Craniofacial anomalies and the sense of smell .Tri-State Craniofacial Conference , Cincinnati, OH. .

Galla J, Duncan H (11-1995. )Mortality in dialysis patients with chemosensory disorders (CSD) and malnutrition .American Society of Nephrology,

Duncan H (02-1994. )Patients with taste or smell dysfunction .Association for Research in Otolaryngology,

Duncan H, Smith D (07-1993. )Modifiability of NaCl taste aversion generalization functions .International Symposium on Olfaction and Taste,

Seiden A, Duncan H (10-1993. )The further characterization of dysgeusia and implications for therapy .AAO-HNS Meeting,

Duncan H, Frank R, Kues J, Heacock P, Heile S, Norton P, Galla J (11-1993. )Chemosensory disorders (CSD) in hemodialysis (HD) patients as assessed by inventory .American Society of Nephrology,

Myer C III, Duncan H (12-1993. )Assessment of olfactory defecits in children: results with an odor identification tast .Society for Ear, Nose and Throat Advances in Children,

Symposium

Duncan H (06-2007. )Taste and Smell Function and Dysfunction .The Christ Hospital .

Duncan H (09-2007. )Vascular Access Clinical Trials in the Dialysis Unit .Cincinnati, OH.

Duncan H (05-2004. )Taste and Smell Dysfunction in the Renal Patient .Long Island, NY.

Duncan H (01-2003. )Taste and Smell Dysfunction and Implications for Patients with Kidney Disease .Kansas City.

Duncan H (09-2003. )Vascular Access Dysfunction: What, Why and How? .

Duncan H (04-2002. )Taste and Smell Dysfunction in Patients with Kidney Disease .Chicago, IL.

Duncan H (10-2002. )Taste and Smell Dysfunction in Patients with Kidney Disease .Louisville, KY.

Duncan H (03-1999. )Taste Dysfunction .Cincinnati, OH.

Duncan H (11-1998. )Why is it Hard to Control Our Mouths? Insights from sensory science .Cincinnati, OH.

Duncan H (10-1996. )Recent Advances in Taste and Smell .Queretaro, Mexico.

Duncan H (02-1994. )Patients with taste or smell dysfunction .Clearwater, FL.

Duncan H (07-1993. )Evaluation of taste dysfunction at the University of Cincinnati Taste and Smell Center .Sapporo, Japan.

Duncan H (07-1993. )Practice on taste disorders at the University of Cincinnati .Tokyo, Japan.

Duncan H (12-1993. )Smell and Taste .University of Pennsylvania Smell and Taste Center and Department of Otorhinolaryngology: Head and Neck Surgery, Philadelphia, PA.

Honors and Awards

1994 Moskowitz Award for Excellence in Taste and Smell Psychophysics

1995 Research Mentor Award for Alpha Omega Alpha Student Research Fellowship

2006 Extra Mile Award for Parent Volunteer of the Year, Cincinnati Parents for Public Schools

Post Graduate Training and Education

1976M.A., Psychology, Columbia University, ,New York, NY

1984Ph.D., Psychology, The American University, ,Washington, D.C.

Certified, Clinical Research Coordinator, ACRP,

1984-1987 Postdoctoral Fellow, Behavioral Immunogenetics Program, Monell Chemical Sciences Center, ,Philadelphia, PA

Professional Affiliation

Association of Clinical Research Professionals

Research Coordinators Group of Internal Medicine University of Cincinnati College ,

Contact Information

Academic - Medical Sciences Building
Room 6213
CincinnatiĀ  Ohio, 45267-0585
Phone: 513-558-5471
Fax: 513-281-0302
heather.duncan@uc.edu